skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Impact of CD200-Fc on dendritic cells in lupus-prone NZB/WF1 mice

Abstract

Abnormal expression of CD200/CD200R1 may contribute to the immunologic abnormalities in patients with systemic lupus erythematosus (SLE). This study aimed to assess the function of CD200/CD200R1and impact of CD200-Fc on dendritic cells in lupus-prone NZB/WF1 mice. Female NZB/WF1 mice were treated with CD200-Fc or control for 4 weeks. Plasma samples were collected to measure autoantibody levels. The expression levels of CD200/CD200R1 in peripheral blood mononuclear cells (PBMCs) and splenocytes were examined. The percentage of CD200/CD200R1-positive cells in splenocytes from NZB/WF1 mice was lower than that of C57BL/6 mice (p<0.05). The plasma level of anti-dsDNA was significantly higher in NZB/WF1 mice than C57BL/6 mice (p<0.001). However, the anti-dsDNA levels decreased (p=0.047) after CD200-Fc treatment. Finally, CD200-Fc reduced the levels of IL-6 (p=0.017) and IL-10 (p=0.03) in the dendritic cell culture supernatant. This study suggests that the immunosuppressive CD200/CD200R1 signaling pathway might be involved in the immunopathology of NZB/WF1 mice; the present results merit further exploration of agents that can modulate the CD200/CD200FR1 pathway as a therapy for human lupus.

Authors:
 [1];  [1];  [1];  [1]
  1. Peking Union Medical College Hospital, Beijing (China). Key Lab. of Rheumatology & Clinical Immunology, Dept. of Rheumatology & Clinical Immunology; Chinese Academy of Medical Science (CAS), Beijing (China). Clinical Immunology Center
Publication Date:
Research Org.:
Washington Univ., St. Louis, MO (United States)
Sponsoring Org.:
National Natural Science Foundation of China (NNSFC); Beijing Municipal Natural Science Foundation; USDOE
OSTI Identifier:
1326665
Grant/Contract Number:  
SC0001035; 81325019; 81172859; 81273312; 81302594; 81550023; 7141008; 20120217; 2011-4001-02
Resource Type:
Journal Article: Accepted Manuscript
Journal Name:
Scientific Reports
Additional Journal Information:
Journal Volume: 6; Journal ID: ISSN 2045-2322
Publisher:
Nature Publishing Group
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES; Lupus; CD200-Fc; NZB/WF1; Lupus nephritis

Citation Formats

Yin, Yufeng, Zhao, Lidan, Zhang, Fengchun, and Zhang, Xuan. Impact of CD200-Fc on dendritic cells in lupus-prone NZB/WF1 mice. United States: N. p., 2016. Web. doi:10.1038/srep31874.
Yin, Yufeng, Zhao, Lidan, Zhang, Fengchun, & Zhang, Xuan. Impact of CD200-Fc on dendritic cells in lupus-prone NZB/WF1 mice. United States. doi:10.1038/srep31874.
Yin, Yufeng, Zhao, Lidan, Zhang, Fengchun, and Zhang, Xuan. Mon . "Impact of CD200-Fc on dendritic cells in lupus-prone NZB/WF1 mice". United States. doi:10.1038/srep31874. https://www.osti.gov/servlets/purl/1326665.
@article{osti_1326665,
title = {Impact of CD200-Fc on dendritic cells in lupus-prone NZB/WF1 mice},
author = {Yin, Yufeng and Zhao, Lidan and Zhang, Fengchun and Zhang, Xuan},
abstractNote = {Abnormal expression of CD200/CD200R1 may contribute to the immunologic abnormalities in patients with systemic lupus erythematosus (SLE). This study aimed to assess the function of CD200/CD200R1and impact of CD200-Fc on dendritic cells in lupus-prone NZB/WF1 mice. Female NZB/WF1 mice were treated with CD200-Fc or control for 4 weeks. Plasma samples were collected to measure autoantibody levels. The expression levels of CD200/CD200R1 in peripheral blood mononuclear cells (PBMCs) and splenocytes were examined. The percentage of CD200/CD200R1-positive cells in splenocytes from NZB/WF1 mice was lower than that of C57BL/6 mice (p<0.05). The plasma level of anti-dsDNA was significantly higher in NZB/WF1 mice than C57BL/6 mice (p<0.001). However, the anti-dsDNA levels decreased (p=0.047) after CD200-Fc treatment. Finally, CD200-Fc reduced the levels of IL-6 (p=0.017) and IL-10 (p=0.03) in the dendritic cell culture supernatant. This study suggests that the immunosuppressive CD200/CD200R1 signaling pathway might be involved in the immunopathology of NZB/WF1 mice; the present results merit further exploration of agents that can modulate the CD200/CD200FR1 pathway as a therapy for human lupus.},
doi = {10.1038/srep31874},
journal = {Scientific Reports},
number = ,
volume = 6,
place = {United States},
year = {Mon Aug 22 00:00:00 EDT 2016},
month = {Mon Aug 22 00:00:00 EDT 2016}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Save / Share: